BioHarvest Sciences (NASDAQ:BHST) Releases Earnings Results
by Kim Johansen · The Markets DailyBioHarvest Sciences (NASDAQ:BHST – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01, Zacks reports. The business had revenue of $9.07 million for the quarter, compared to analyst estimates of $9.24 million. BioHarvest Sciences had a negative return on equity of 1,041.86% and a negative net margin of 36.33%.
Here are the key takeaways from BioHarvest Sciences’ conference call:
- Q4 revenue was $9.1M (+25% YoY) and full‑year revenue was $34.5M (+37% YoY), with Q4 adjusted EBITDA of $0.5M, improved gross margins (~59%), and year‑end cash of $23M, reflecting materially stronger profitability and liquidity.
- The VINIA direct‑to‑consumer business exceeded 85,000 active users, earned the #1 U.S. resveratrol brand position, and the new VINIA Blood Flow Hydration launch is showing strong early traction (15% of new‑customer revenue and ~4.8–4.9 ratings), prompting a shift to digital marketing to reach younger cohorts.
- The CDMO unit hit a major technical milestone by completing stage one for a rare fragrance plant (first‑ever stable cell culture), retains 20% ownership of resulting compositions, has four active third‑party programs (including Tate & Lyle and Saffron Tech), and expects external CDMO revenue to rise toward $4–6M in 2026.
- Management is investing heavily in CDMO and manufacturing capabilities (AI, process engineering, elicitation center) and increasing marketing spend, which will make near‑term results lumpy and raise operating expenses but is presented as a deliberate trade‑off to accelerate growth in 2027–2028.
BioHarvest Sciences Trading Up 0.6%
Shares of NASDAQ BHST traded up $0.03 during mid-day trading on Wednesday, reaching $4.37. 4,311 shares of the company’s stock were exchanged, compared to its average volume of 26,138. The company’s 50-day moving average is $4.61 and its 200-day moving average is $6.65. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.02 and a current ratio of 1.35. The firm has a market capitalization of $85.68 million, a price-to-earnings ratio of -6.49 and a beta of 1.14. BioHarvest Sciences has a 52-week low of $4.10 and a 52-week high of $12.80.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of BHST. Geode Capital Management LLC acquired a new stake in shares of BioHarvest Sciences during the fourth quarter valued at about $61,000. HRT Financial LP acquired a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $75,000. Jane Street Group LLC purchased a new position in shares of BioHarvest Sciences during the 4th quarter worth approximately $145,000. Alyeska Investment Group L.P. purchased a new position in shares of BioHarvest Sciences during the 4th quarter worth approximately $3,929,000. Finally, Marshall Wace LLP acquired a new stake in BioHarvest Sciences in the 4th quarter valued at approximately $110,000.
Analysts Set New Price Targets
BHST has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Friday. Roth Mkm initiated coverage on shares of BioHarvest Sciences in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $13.00.
Check Out Our Latest Analysis on BHST
BioHarvest Sciences Company Profile
BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.
The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.